Savient: FDA Does Not See More Trials for Gout Drug

Savient Pharmaceuticals Inc said U.S. health regulators do not expect additional trials to be required for its experimental gout drug, which was denied approval in July, and the resubmission could take up to six months for review.
Yahoo! Finance UK & Ireland